|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder 显示文摘 | Zinner N | 2007 | Expert Opin Pharma2007，8，4： | 1 |
| 2 | A phase 3, muhicenter, open- label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer显示文摘 | Mcleod D Zinner N Tomera K | 2001 | Urology2001，58，5： | 1 |
| 3 | AUC/MIC relationshipstl to different endpoints of the antimicrobial effect显示文摘 | ZINNER S H VOSTROV S N | 2002 | J Antimicrob Chemother2002，50，4： | 1 |
| 4 | A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer显示文摘 | Mcleod D Zinner N Tomera K | 2001 | Urology2001，58，5： | 1 |
| 5 | Duloxetine versus placebo in the treatment of stress urinary incontinence显示文摘 | Norton P A Zinner N R | 2002 | American Journal of Obsterics and Gynecology2002，187，1： | 1 |
| 6 | Trospium chloride improves overactive bladder symptoms:a multicenter phase Ⅲ trial显示文摘 | ZINNER N GITTELMAN M HARRIS R | 2004 | J Urol2004，171，61： | 1 |
| 7 | Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI)显示文摘 | Zinner N Dmochowski R Miklos J | 2002 | Neurourol Urodyn2002，21，4： | 1 |
| 8 | A phase 3,multicenter,open-label,randomized study of abarelix versus leuprolide acetate in men with prostate cancer显示文摘 | McLeod D Zinner N Tomera K | 2001 | Urology2001，58，： | 1 |
| 9 | Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg:results of a 12-week,multicenter,open-label,flexible-dosestudv显示文摘 | Chancellor MB Zinner N Whitmore K | 2008 | ClinTher2008，30，： | 1 |
| 10 | Managing the prngression of lower urinary tract symptoms/benign prostatic hyperplasia:therapeutic options for the man at risk显示文摘 | Emberton M Zinner N Michel MC | 2007 | BJU Int2007，100，2： | 1 |
| 11 | Aphase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer 显示文摘 | McLeod D Zinner N Tomera K | 2001 | Urology2001，58，： | 1 |
| 12 | Magnetic structure of an imbalanced Fermi gas in an optical lattice 显示文摘 | Wunsch B Fritz L Zinner N T | 2010 | Physical Review A2010，81，01： | 1 |
| 13 | Efficacy of solifenacin inpatients previously treated with tolterodine extended release 4 mg: resultsof a 12-week, multicenter, open-label, flexible-dose study显示文摘 | Chancellor MB Zinner N Whitmore K | 2008 | Clin Ther2008，30，10： | 1 |
| 14 | Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: thera- peutic options for the man at risk显示文摘 | Emberton M Zinner N Michel MC | 2007 | BJU Int2007，100，： | 1 |
| 15 | A phase 3,multicenter,openlabel,randomized study of abarelix versus leuprolide acetate in men with prostate cancer显示文摘 | McLeod D Zinner N Tomera K | 2001 | Urology2001，58，5： | 1 |
| 16 | Efficacy of solife- nacin in patients previously treated with toherodine extended re- lease 4 rag: results of a 12-week, multicenter, open-label, flexi- ble-dose study 显示文摘 | Chancellor MB Zinner N Whitmore K | 2008 | Clin Ther2008，30，： | 1 |
| 17 | A phase 3, muticenter, open- lable,randominzed study of abarelix versus leuprolide acetate in men with prostate cancer显示文摘 | Meleod D Zinner N Tomerra K | 2011 | Urology2011，58，5： | 1 |
| 18 | Darifenacin:a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder显示文摘 | Zinner N | 2007 | Expert Opin Pharmacother2007，8，4： | 1 |
| 19 | R0700004, a selective α1A-adrenoceptor ant-agonist does not improve LUTS in men with BPH显示文摘 | Blue D Zinner N | 2002 | J Urol2002，，： | 1 |
| 20 | Efficacy,tolerability and safety of darifenacin,an M(3) selective receptor antagonist:an investigation of warning time in patients with OAB显示文摘 | Zinner N Susset J Gittelman M | 2006 | Int J Clin Pract2006，60，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员